Home / Transcripts / Nanoform Finland Oyj (NANOFH) · February 26, 2026

Nanoform Finland Oyj (NANOFH) Earnings Call Transcript

February 26, 2026

Nasdaq Helsinki FI Health Care Life Sciences Tools and Services earnings 34 min

Earnings Call Speaker Segments

Operator operator
#1

Thanks for joining this conference call. At the start of today's call, attendees will be able to listen only. When we get to the questions-and-answers session, participants can pose questions by pressing *5 on their phone keypad. At this point I'll turn the conference over to the speakers. Please proceed.

Henri von Haartman executive
#2

Good morning, everyone, and a very warm welcome to the presentation of Nanoform's report for the fourth quarter and the full year 2025. I'm Henri von Haartman, and joining us today are our CEO, Edward Hæggström; our CFO, Albert Hæggström; our CCO, Christian Jones; and our CDO, Peter Hänninen, who will all present. This presentation is being webcast via Investor-Call, and you can also dial in and listen over the phone. The slides you see here during the webcast are available as well on our website, under the investor section. We'll wrap up with a Q&A, and those of you calling in will be able to put questions forward. Today's agenda opens with strategy and the key business highlights, moves on to financials, then commercial, and we finish with product kernels and biologics. With that, I'll hand over to our CEO and Founder, Edward Hæggström — please go ahead.

Edward Hæggström executive
#3

Thank you, Henri, and welcome from my side as well. As mentioned, a great deal of the emphasis in this report is now going to be on 2025 in total. Next slide, please. I'd like to begin with a photo. It comes from our facility. It was taken at the Capital Markets Day that took place on December 15, 2025. In it, you can see Dr. Winfried Ness, who serves as Director of IP. He is talking about our IP strategy for the next 5 years. That is going to matter enormously to us, since up to now the task has been constructing a plant. Going forward, it will really be about employing that plant in a strategically smart manner to accomplish what our mission is, namely making the nanoforming technology a globally dominant technology. Next slide, please. The strategy that was unveiled and launched at that time goes by the name the breakthrough strategy. We are going to break the wall in two places, one for small molecules and one for large molecules. Next, please. Here you can see an outline. Essentially, on the small-molecule side, we will have patients treated with nanoformed medicines within the next 5 years. As for the biologics part, we will have commercially relevant clinical data to support what we need to do in the shift from IV to subcutaneous.

Edward Hæggström executive
#4

This represents a significant technological change within the industry, and we intend to be a participant in it. Could we go to the next slide, please. What you see here are the mid-term business targets that were also disclosed at that same moment: three nanoformed medicines, revenue growth above 50% CAGR, and an EBIT margin above 30% by 2030. Next, please. Quite a lot has taken place over the course of 2025. I'd like to divide these into four groups. We have created new IP, and we have brought our scale up to the level required for commercial relevance at industrial scale. We have additionally produced GMP batches on nanoenzalutamide and nanoapalutamide, and we are ready to do the same on nanoencorafenib. On the commercial side, we have struck deals with five countries, four in EU and one outside EU. That is the primary commercial driver at present for the kernels, which forms part of the strategy we are now carrying out. We have also secured an EU-wide license to commercially manufacture API. We have obtained a distributor in South Korea, which reinforces our presence in Asia. Beyond that, we received a €5 million loan from Business Finland essentially to strengthen our kernel IP and that effort. We have carried out change negotiations in order to shape our workforce.

Edward Hæggström executive
#5

Over the past 5 years, our focus was on building. The coming 5 years, though, will be dedicated to cashing in. Finally, we now have preclinical data on nanotrastuzumab — which is essentially a first for us when it comes to making the biologics offering matter, both for us and for others. Let's go to the next slide, please. Here you can see the near-term business targets for this year. The cash burn below €10 million, really, Albert will speak to that. Then the filing of the first marketing authorization, and to me this is a very, very big thing, because this is where the regulatory game now begins, along with the preparations for it. This serves as a preamble for our launch of the nanoenzalutamide. Then there's an increased number of non-GMP and GMP projects signed this year. And finally, signing, developing, and licensing commercial supply agreements with several of the product kernels. This really moves the product kernel game forward in a commercial setting. Next slide, please. At this point I hand things over to Albert. Albert, please.

Henri von Haartman executive
#6

Thanks, Edward. Now let's turn to a few of the numbers. Starting on the left-hand side with proposals sent, you can see a clear upward shift here versus prior years.

Albert Hæggström executive
#7

I'm speculating a bit in the header here — could this be a modest shift happening in the industry now? The industry's early-stage pipelines have gone through four very tough years. A lot of the large CDMOs have watched very few projects arrive. Big pharma has kept its attention on late-stage work. Investors have done the same. We're all aware that if you don't also fill the pipeline at the early stage, eventually you'll run out of late-stage projects. I've noticed that over the past months and quarter we've met several people who have begun saying they want to put more emphasis on early stage and on new technologies capable of delivering a clear edge. Overall, I'd frame this somewhat positively: the fact that we're also seeing plenty of requests for proposals go out may be a signal that the industry is recovering at the earlier stage as well. That, naturally, benefits us. On the count of projects signed, as you can see on the right-hand side, we're at roughly the same levels as in recent years.

Albert Hæggström executive
#8

But we've now completed more GMP projects, and those tie back to our product kernels. Keep in mind that in the CMD, we said our goal for the next 5 years is to raise the GMP project share from the earlier 5% up to the industry figure of 25%. That's a significant move in the right direction. If we then turn to income and EBITDA on the left-hand side, you can see on the income side that 2025 brought a clear rise in income. We hit a record level of revenue. We hit a record level of other operating income, and we also, for the first time, had income from share of results of other associated companies. The nice thing about Nanoform is that since we carry a high gross margin, any growth in revenue or in income flows straight through to the profit and loss account. You can see that on the right-hand side — EBITDA improved clearly versus last year thanks to the higher income. If we then move to cash burn, the same picture shows up there. Especially now, after wrapping up the change negotiations, which will give us €5 to €6 million in reduced costs, that means we feel very comfortable about reaching the cash burn target of below €10 million in 2026.

Albert Hæggström executive
#9

So naturally, given that we closed the year with €24 million in cash, that leaves us with a very comfortable runway ahead until we reach cash flow positive. One key point to keep in mind is that the 2026 cash flow target does not factor in any significant milestones. If we sign deals on other kernels, or when milestones come in from things like nanoenzalutamide or others, that will add a further positive effect on cash flow. We're comfortable with our cash position, and with the fact that cash burn will be considerably lower once again this year. With that, I'll pass it to Christian.

Christian Jones executive
#10

Thanks, Albert. I'll take the commercial part. Let's move to the next slide. As Albert said, it's been a record year for proposals sent — 96 went out last year. I see two reasons for that. First, the market may be coming back. The XBI index is at its highest level in the last 52 weeks. That's 35% growth on last year. The second factor is the kernels. Our work there has definitely drawn a lot of attention to Nanoform's technology. We've opened a new market in Asia, and we're now starting to see the real impact of that from Japan and from South Korea. We've built good foundations in Europe and the US, and that's beginning to pay dividends. Then there's the biologics technology. We made some really good announcements last year about our biologics technology, and that has brought a significant increase in interest in it and in Nanoform. Of the many proposals sent, our hit rate now is similar to what it was before. We expect this to be a very positive aspect for us going forward. As Albert and Edward mentioned, we have signed five countries on nanoenzalutamide for commercialization, and many more are to come.

Christian Jones executive
#11

We’re eager to give you an update once we have further details on that. Nanoencorafenib was outlicensed in the prior year, and a special company, Brafmed, was set up in partnership with a private equity firm and also AforA. That has allowed us to move a single product into an SPV-type vehicle, where we can then hold a percentage ownership in that company, receive payment for the manufacturing we perform during development, and participate in the returns when this product is outlicensed to pharma companies down the road. Asia expansion: so, as I noted, we moved into Japan with support from CBC, our trading agent in Japan, and into South Korea with support from A&LS Pharma, our agents there. Our VP of Business Development in Asia is in Japan right now, on a very successful trip, and will be in South Korea next week. It’s a market showing a significant amount of interest in Nanoform’s technology, in the technology’s miniaturization capability. I think especially in South Korea, there’s a lot of interest around the biologics technology, and also our products and our kernels. All of this, I think, was really underpinned by the great work done on securing a commercial manufacturing license.

Christian Jones executive
#12

For our big pharma innovator clients, the key issue is handling risk just as much as spotting value. The fact that we can claim we aren't merely a clinical company — we can manufacture at commercial scale, and we hold commercial regulatory approval for our facility — is a major advantage, and it will definitely be a help going forward, both for the kernels and for our innovator clients ahead. And finally, the positive data we generated late last year on in vivo biologics. That was highly meaningful, since we demonstrated that using nanoformed particles in a nonaqueous suspension, we achieved AUC, Cmax, and Tmax similar to a hyaluronidase-based formulation — the marketed Roche Genentech product backed by Halozyme's technology. On a separate note, our customers have reported very encouraging data on ultra-high concentration formulations of their monoclonal antibody products. We haven't discussed that much, but I'd say it may be even more exciting. We're hoping to share more on that later this year as those projects move along. Turning to enzalutamide, which right now is truly our lead product among our kernels.

Christian Jones executive
#13

Our goal is to hit commercial launch in Europe during 2028. To get there, we must obtain marketing authorization. We also need to maximize the market value, and we simply need to plan strategically. Over the last year, we've worked diligently to ensure our regulatory pathway is clear and that we can submit our dossier in a timely manner. In parallel, we've also been manufacturing materials and holding commercial negotiations. As I mentioned, several European countries have already signed, and we expect to launch this product in June 2028. As we move through the end of '27 into '28 and '29, the focus will be on building up sufficient inventory and stock for that product launch. Now I'll hand things over to Peter, who will walk you through the kernels and biologics.

Peter Hänninen executive
#14

Thanks, Christian. Perhaps I'll pick up roughly where you left off and discuss the kernels. Maybe first a reminder of the reason we've been building this product kernel pipeline alongside the customer projects. The fundamental notion has always been quite straightforward: to speed up even more how quickly the industry takes up our technology offering, we've aimed to kick off these nanoparticle-enabled formulation developments so as to demonstrate in actual practice what the technology makes possible for products. And, naturally, as we've observed, now to generate the possibility of commercially appealing partnering opportunities. During this quarter, we were, needless to say, very pleased to carry out, as Christian noted, the outlicensing development and commercialization agreement and investment into nanoencorafenib by AforA and IMGA. In numerous respects, this represented a significant milestone for moving that particular product kernel toward the clinic, yet it also highlighted the wider opportunity surrounding the product kernel pipeline. As a quick reminder regarding nanoencorafenib, Nanoform continues to be a major shareholder in Brafmed, and going forward Brafmed will pay Nanoform service fees and low-single-million development milestones, plus up to mid-single-digit tiered royalties once commercialization occurs. We have, obviously, also kept advancing development of the remaining kernels, and in December, as was mentioned, we produced the first GMP batches of nanoapalutamide.

Peter Hänninen executive
#15

Now moving to biologics, a space that's getting more and more interesting, as Christian also mentioned. We genuinely see a big market taking shape around subcutaneous delivery of monoclonal antibodies, and we expect that to be a major theme across the market as a whole, and for Nanoform too over the years ahead. There are three key points on this slide. First, our belief is that subcutaneous delivery is going to become the dominant standard for both new and marketed biologics. That represents a major shift away from what is today a predominantly IV market. Second, to make this shift possible at scale, suspension formulations will matter, since they can support high drug concentrations, which in turn translate into lower injection volumes. Lower injection volumes can help avoid complex formulations as well as the use of devices. That is also why we think suspensions will turn into the preferred technology choice for subcutaneous delivery going forward. Third, and crucially for Nanoform in my view, particle properties are truly critical to suspension performance, including robustness, injectability, and the ability to reach meaningful concentration levels. Since these particle properties matter so much, we're confident that Nanoform's technology can become a technology of choice for enabling subcutaneous delivery. If we then move to the concrete example Christian also brought up, this slide covers preclinical results comparing nanotrastuzumab, a hyaluronidase-free nonaqueous nanoparticle suspension of trastuzumab, against Herceptin Hylecta, the commercial product that has hyaluronidase in the formulation.

Peter Hänninen executive
#16

In this 21-day Göttingen minipig study, the area under the curve, Cmax, and Tmax for nanotrastuzumab came very close to matching Genentech and Roche's reference product. Beyond that, nanotrastuzumab was well tolerated too, which the pathological, clinical, and immunological readouts support. At Nanoform, what makes this matter isn't merely that we have a strong data point from this particular study — it's that, alongside the data our customers are producing, it backs the wider thesis that suspension-based, particle-enabled approaches can genuinely offer a compelling route to enabling subcutaneous delivery, and in this specific case that includes doing so without depending on hyaluronidase. It further demonstrates that formulation and particle engineering can truly deliver clinically relevant performance for biological medicines. I also want to underscore the strategic statement that appears on the slide behind that, since I believe it captures the commercial opportunity here very effectively. The majority of pharmaceutical and biotech companies developing antibody products today lack a technology capable of enabling subcutaneous versions of those products. We see an enormous opportunity to collaborate with those drug developers to enable subcutaneous versions of their products. As we all know, subcutaneous delivery brings clear advantages when it comes to convenience, patient experience, and healthcare system efficiency — if you avoid having to go to the hospital, for instance, for an IV infusion.

Peter Hänninen executive
#17

For any innovator or biosimilar developer able to provide a subcutaneous form of their product, we think that is genuinely a valuable point of differentiation in the market. Now, placing that within the context of this market structure — and this was also a slide we presented at the Capital Markets Day held some months ago — it illustrates why a lot of biologics developers right now are actively seeking alternatives. As that slide demonstrates, when it comes to higher-dose biologics, the sole technology available to date, essentially for every purpose, has involved employing Halozyme's hyaluronidase enzyme to break down subcutaneous tissue so that a larger volume can be injected. Across the last decade, Halozyme has in effect built this market for subcutaneous delivery of biologics through putting together those target-based exclusive agreements. That has been extremely, extremely profitable for the company, yet it has simultaneously meant that for each of these targets there are multiple companies unable to access that technology, and those companies have consequently been eager to identify an alternative that would allow a subcutaneous version of the product. Implicit in this slide, I would add, is that these first 10 years represent only the beginning.

Albert Hæggström executive
#18

Over the coming 10 years, a significant portion of the remaining product developers will want to bring in their own subcutaneous options as well. Naturally, from where we sit, this is a highly significant dynamic. Through collaboration with our customers — and many of them we already partner with on either small molecules, biologics, or both — we aim to help make this competition possible within the subcutaneous space and, naturally, in the end to deliver alternatives for patients, physicians, and the healthcare systems. If you take this macro trend of subcutaneous becoming the dominant standard and combine it with the practical demands of high concentrations and low injection volumes, along with the present market structure that is pushing toward alternative technologies, we think the conditions are increasingly favorable for our approach at Nanoform and for partners to work with us on suspension-enabled subcutaneous biologics. That, I believe, is also what Christian was alluding to when he spoke about the interactions in the market. With that, I'll hand things over to Henri.

Operator operator
#19

Should you want to pose a question, dial *5 on your phone keypad to join the queue. To pull your question, dial *5 once more on your telephone keypad. Sami Sarkamies of Danske Bank Markets has the next question. Please proceed.

Sami Särkämies analyst
#20

Hello. There are three questions I'd like to ask, and we'll go through them one at a time. First, regarding the income growth outlook: you're aiming for a CAGR above 50% through 2030. I just want to get a sense of whether you believe that goal is achievable in this year as well, or whether top-line progression should be expected to be weighted more toward the back end?

Albert Hæggström executive
#21

If I take that one — hi, Sami, that's a great question. Since we don't provide financial guidance for the year, what we do say beyond that is that cash burn is going to come in under €10 million. When it comes to top-line growth, here's how I think about it: at the start — let's say this year, next year, and so on — the numbers are smaller, so relatively speaking it's of course easier to achieve a higher percentage growth than at the end of the period, when you have larger numbers; at that point, the absolute growth required to hit the CAGR 50% would be higher. Then, of course, you'll have products on the market, which makes it easier. What I think we're thinking internally is that, from a percentage point of view, we're targeting an average of 50% over the period, or more than 50% over the period.

Sami Särkämies analyst
#22

All right, moving to the second question, which concerns the milestone outlook. You're aiming for a €10 million burn rate absent milestones, but considering those possible milestones, which ones might you be able to record this year? Would they tie to programs already in place, or to entirely new projects?

Albert Hæggström executive
#23

Yeah, so that's a great question. Milestones can come from smaller ones tied to individual kernels, where you'd have a single event that triggers some milestone — say, for example, a market approval or something along those lines. They could also be milestones tied to kernels that we sign, for instance, at signature if we sign kernels. These milestones are, of course, then multiplied by the percentage of the milestone that we own. In apalutamide, we own 100%, and in some others we own 100%, and in enzalutamide we own 25% of the project. They could come both from kernels we've talked about, but they could also come from kernels we haven't mentioned, sort of more publicly. They could come from new ones. Let's see. Timelines are always hard to estimate, but it's fair to say that we're targeting several signings during this year, and the milestones from this could still be significant, but we haven't included them in our target of less than €10 million in cash burn.

Sami Särkämies analyst
#24

Thank you. So the last thing I want to ask about is the Bioline platform. At what point do you expect it to be set for initial human trials involving Bioline?

Albert Hæggström executive
#25

If I begin with that, at present we’ve got a line that, strictly speaking, is already where it has to be for that purpose. GMP stamps still have to be obtained, and to obtain them, we need someone to put money into that line, since under our cess-side strategy we took the approach of “build and they will come,” but now with Bioline we want a setup in which other parties cover the upgrades required to secure the stamps. That’s difficult to predict, but we’re actively working on it at this moment, and naturally, my goal is to get there as fast as we can, because market evolution won’t wait for us.

Sami Särkämies analyst
#26

What kind of timeline are we looking at? Is it a 1-year delay, 3 years, 5 years? What might that be?

Edward Hæggström executive
#27

I wouldn’t call it a delay. My view is that we spent the earlier years developing the technology, and from a technical-specification standpoint it’s now where we need it to be at industrial scale. On the other side of that, Albert, perhaps you could speak to the financial side?

Henri von Haartman executive
#28

Naturally, we're in discussions with a lot of people, and this also concerns the broader momentum within the industry — namely, how quickly we can make it happen. Our goal, obviously, is to get it done within this year already. Peter is among those heavily involved in this effort as well — Peter, would you like to weigh in?

Peter Hänninen executive
#29

Glad to do that. I think a big part of this is now about getting the customers we have on the biologics side aligned, and the fact that they're obtaining solid animal data from their own projects using our particles is, of course, quite encouraging, and together we're actively looking at moving toward the clinic. As Edward mentioned, that's going to need a GMP facility for the technology, or the technology would have to get a GMP stamp. Our best guess is that, from the moment we pull the trigger on setting up something like that ourselves with partners, or some combination of that, wherever it ends up landing, it would likely take around 24 months before we could actually supply clinical material. ASAP is the answer, but at the same time, everyone realizes you can't reach GMP in 1 day. Getting that in place will take some work and time. There's a lot of, I'd say, positive momentum building behind it, and right now we're very actively examining, together with our customers and partners, how to bring this to clinic.

Sami Särkämies analyst
#30

Thank you. That covers everything I wanted to ask.

Operator operator
#31

That brings us to the end of the question-and-answer portion. I'll now return the floor to the speakers in case they have any closing remarks.

Henri von Haartman executive
#32

Thanks, operator. Speaking for Nanoform, I want to express appreciation to everyone who joined us today. Should any questions remain, simply get in touch with us. Our homepage has the contact details, including phone numbers and email addresses. We hope each of you enjoys a wonderful Thursday afternoon and evening. Thanks, and...

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nanoform Finland Oyj transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Nanoform Finland Oyj earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.